Whitepapers

OTAVA Ltd. offers a new set of target-focused libraries with Enhanced Intellectual Property Potential (EIPL®). This set of libraries with a variety of novel compounds is an excellent starting... Read more...

To say the environment around biosimilars is fluid would be an understatement. With fluidity comes uncertainty and with uncertainly comes opportunity. Many industry pundits are evaluating the... Read more...

Just finished a study to understand why consumers are using social media and have found some compelling insights into where & how to effectively engage and connect with patients & health... Read more...

The social media space has expanded geometrically in recent years...Social media has become an extremely important tool in listening & learning about consumers, market perceptions, & most... Read more...

Consistent with ISR's mission, this research tackles significant Late Phase industry issues with rigor and insight. Respondents discuss in detail their plans for study conduct and outsourcing across

... Read more...

This whitepaper outlines the use of Point Of Care (POC) testing in Clinical Trials, including the policies and procedures involved and the benefits POC can bring to trials across the globe. Point Of

... Read more...

When the H1N1 pandemic appeared in early 2009, it was a global nightmare. But advances in disease surveillance and vaccine production technology enabled the scientific and medical communities to... Read more...

Congress is under pressure to cut back on intellectual property rights in drugs produced by biotechnology so as to encourage the marketing of biosimilars. The underlying conventional wisdom is that

... Read more...

What should be available to the industry is a 360 degree assessment of the performance, drivers, motivations, hesitations, and leading edge techniques of patients, investigators, pharmaceutical... Read more...

This free primary market research report is based on the findings from 112 biotechnology executives and clinical development decision-makers at biotechnology companies. All the data is revealed and... Read more...

Explore Target Product Profile development and commercially driven drug development strategies for biotech and drug development companies. In this presentation by Thomas Marten, founder of... Read more...

Pharmaceutical and biotech Business Development, Marketing and Strategic Planning Groups need an early read on opportunities, but oftentimes don’t have time or budget for extensive market... Read more...

Oftentimes small pharma and biotech companies make key licensing and portfolio development decisions with limited data or poor information due to the high costs of conducting large scale market... Read more...

Technological advancements and social media tools are transforming the world in a way we never thought possible just a few short decades ago. Easy access to a wide variety of information and the... Read more...

This is an executive summary of a substantial market research study based on interviews with 44 biotechnology company representatives, rating 130 unique projects with CROs. Respondents graded 10

... Read more...